Neuro-Oncology News

The FDA accepted the resubmission of a new drug application for lutetium Lu 177 dotatate for treatment of adults with unresectable or metastatic, progressive, well-differentiated, somatostatin receptor-positive neuroendocrine tumors.

An FDA advisory committee expressed its support for gemtuzumab ozogamicin as part of combination therapy for acute myeloid leukemia; ABP 215, a biosimilar candidate to bevacizumab; and chimeric antigen receptor T-cell product tisagenlecleucel-T suspension for relapsed/refractory B-cell acute lymphoblastic leukemia.

The NIH established the Kids First Data Resource Center, a pediatric cancer and rare disease data program that will enable clinicians and researchers to collaborate and access multiple genomic datasets.

Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study results published in The Oncologist.

Researchers have identified positive and negative associations between five prediagnostic serum cytokines and subsequent glioma diagnosis.

One-third of insured patients with cancer had out-of-pocket costs that exceeded their expectations, according to study results.

The FDA granted orphan drug designation to SurVaxM for the treatment of patients with glioblastoma, according to the agent’s manufacturer.

The FDA granted orphan drug designation to tesevatinib for the treatment of EGFR-positive non-small cell lung cancer, according to the drug’s manufacturer.

BRAF V600E mutations defined a distinct subset of pediatric low-grade gliomas that had poor outcomes after conventional therapy, according to a combined clinical and genetic analysis.

Whole-body MRI increased detection of abnormalities and new cancers in patients with Li-Fraumeni syndrome, according to results of two studies published in JAMA Oncology.